Compound News and Research

RSS

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

Symphogen announced today that the company will present preliminary Phase 1 data evaluating the company's lead cancer compound, Sym004, at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago.

1 Jun 2011

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, E64d, not only reduces the build-up of β-amyloid in the brains of animal models for Alzheimer's disease, but also results in a substantial improvement in memory deficit.

1 Jun 2011

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion.

1 Jun 2011

Birth control pill safety issues raised

The U.S. Food and Drug Administration (FDA) has announced that it is looking at results from two studies that showed there is a higher risk of blood clots in women taking new birth control pills containing the compound drospirenone. Some brand names include Yaz, Yasmin, Beyaz, Ocella, Loryna, Gianvi, Safyral, Syeda and Zarah.

1 Jun 2011

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational agent peginesatide for the treatment of anemia associated with chronic renal failure in adult patients on dialysis.

31 May 2011

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

AstraZeneca and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors.

31 May 2011

Study suggests new therapeutic targets for virally-induced asthma attacks

When children with asthma get the flu, they often land in the hospital gasping for air. Researchers at Children's Hospital Boston have found a previously unknown biological pathway explaining why influenza induces asthma attacks.

30 May 2011

Long-term exposure to estrogen increases high blood pressure in women

For many years doctors believed the estrogen women consumed in the form of oral contraceptives and hormone replacement therapy pills was good for their patients' hearts. Recent studies however have shown that long-term exposure to estrogen can be a danger to women as it has been associated with high blood pressure, a key link to heart- and brain-attacks.

27 May 2011

Turkey tail mushrooms effective in prostate cancer: study

Preliminary studies have shown that mushrooms used in Asia for medicinal purposes vanquished prostate tumor successfully in mice.

26 May 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds - IMGN901 and SAR3419 - are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.

26 May 2011

Tofacitinib safe and effective for patients with rheumatoid arthritis

Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2 percent in the placebo group. Significant improvements were also observed in the 5 mg BID dose.

26 May 2011

Study to examine whether red wine component could help reduce concussions in pro boxers

UT Southwestern Medical Center researchers are engaging the help of professional boxers and trainers to study whether a component in red wine and grapes could help reduce the short- and long-term effects of concussions.

26 May 2011

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Apollo centre for liver disease and transplantation has completed 100 liver transplantations in less than 4 years with over 90% success rate, creating a milestone in the history of medicine.

25 May 2011

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Today, Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. Biogen Idec continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the company has brought more hope to MS patients through a number of significant milestones.

25 May 2011

Provepharm obtains European marketing authorization for its Methylthioninium Chloride Proveblue

Provepharm, a biotech start-up specialized in the development of pharmaceutical applications, announces today that it has just received official marketing authorization for its Methylthioninium Chloride Proveblue from the European Medicines Agency. This authorization means that clinicians will be able to treat European patients for the first time with this injectable drug based on the active principal methylthioninium chloride Proveblue (TM) (or methylene blue), which embodies the quality and safety characteristics currently required of a pharmaceutical product.

24 May 2011

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company's lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels).

23 May 2011

Elixir DESyne Drug Eluting Coronary Stent System granted CE Mark approval

Elixir Medical Corporation, a developer of product platforms combining state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark for its DESyne Drug Eluting Coronary Stent System for the treatment of coronary artery disease.

23 May 2011

Compound News and Research

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Birth control pill safety issues raised

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

Study suggests new therapeutic targets for virally-induced asthma attacks

Long-term exposure to estrogen increases high blood pressure in women

Turkey tail mushrooms effective in prostate cancer: study

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

Tofacitinib safe and effective for patients with rheumatoid arthritis

Study to examine whether red wine component could help reduce concussions in pro boxers

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Provepharm obtains European marketing authorization for its Methylthioninium Chloride Proveblue

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Elixir DESyne Drug Eluting Coronary Stent System granted CE Mark approval

'Turkey tail' mushroom effectively suppresses prostate tumour development

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Novel compound could become an effective alternative to common narcotic analgesics

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News